Research Industry Presents United Front On Japan Reforms
Strong IP Waiver Opposition
Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.
You may also be interested in...
Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
President announces ‘new effort’ to work with pharmaceutical companies, other nations to increase supply. Details remain in short supply, but Biden says plan will increase domestic production capacity to prepare ‘the next crises.’